Ramsay Stattman Vela & Price Inc. lowered its holdings in Stryker Co. (NYSE:SYK) by 1.7% in the 4th quarter, HoldingsChannel reports. The firm owned 45,592 shares of the medical technology company’s stock after selling 802 shares during the quarter. Stryker comprises approximately 3.0% of Ramsay Stattman Vela & Price Inc.’s holdings, making the stock its 14th largest holding. Ramsay Stattman Vela & Price Inc.’s holdings in Stryker were worth $7,147,000 as of its most recent filing with the SEC.

Other large investors have also bought and sold shares of the company. FMR LLC raised its stake in shares of Stryker by 24.0% during the 2nd quarter. FMR LLC now owns 5,327,862 shares of the medical technology company’s stock worth $899,662,000 after acquiring an additional 1,032,333 shares in the last quarter. Advisors Asset Management Inc. raised its stake in shares of Stryker by 1.5% during the 2nd quarter. Advisors Asset Management Inc. now owns 33,452 shares of the medical technology company’s stock worth $5,649,000 after acquiring an additional 494 shares in the last quarter. Bank of Montreal Can increased its stake in Stryker by 19.1% during the 3rd quarter. Bank of Montreal Can now owns 375,011 shares of the medical technology company’s stock valued at $66,632,000 after purchasing an additional 60,015 shares in the last quarter. Stock Yards Bank & Trust Co. increased its stake in Stryker by 4,138.7% during the 3rd quarter. Stock Yards Bank & Trust Co. now owns 58,325 shares of the medical technology company’s stock valued at $10,363,000 after purchasing an additional 56,949 shares in the last quarter. Finally, MainStreet Investment Advisors LLC acquired a new position in Stryker during the 3rd quarter valued at approximately $2,571,000. Institutional investors and hedge funds own 74.99% of the company’s stock.

In other Stryker news, VP M Kathryn Fink sold 180 shares of the stock in a transaction on Monday, February 4th. The stock was sold at an average price of $176.77, for a total value of $31,818.60. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, VP Michael Damon Hutchinson sold 10,109 shares of the stock in a transaction on Wednesday, February 6th. The stock was sold at an average price of $180.14, for a total value of $1,821,035.26. The disclosure for this sale can be found here. In the last three months, insiders have sold 43,259 shares of company stock valued at $7,515,747. Corporate insiders own 7.30% of the company’s stock.

A number of brokerages have issued reports on SYK. Zacks Investment Research upgraded shares of Stryker from a “hold” rating to a “buy” rating and set a $199.00 price target on the stock in a research note on Monday, February 4th. Cantor Fitzgerald restated a “neutral” rating on shares of Stryker in a research note on Friday, January 18th. Oppenheimer set a $170.00 price target on shares of Stryker and gave the company a “hold” rating in a research note on Friday, November 9th. Finally, SunTrust Banks upped their price target on shares of Stryker to $205.00 and gave the company a “positive” rating in a research note on Monday, February 4th. Seven equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $185.37.

Shares of NYSE SYK opened at $183.38 on Monday. The firm has a market cap of $68.34 billion, a price-to-earnings ratio of 25.09, a P/E/G ratio of 2.25 and a beta of 0.86. Stryker Co. has a one year low of $144.75 and a one year high of $182.69. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.41 and a current ratio of 2.02.

Stryker (NYSE:SYK) last released its quarterly earnings data on Tuesday, January 29th. The medical technology company reported $2.18 EPS for the quarter, topping the consensus estimate of $2.15 by $0.03. Stryker had a net margin of 26.12% and a return on equity of 27.60%. The business had revenue of $3.80 billion for the quarter, compared to analyst estimates of $3.73 billion. Analysts forecast that Stryker Co. will post 8.12 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Investors of record on Friday, March 29th will be given a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a yield of 1.13%. The ex-dividend date of this dividend is Thursday, March 28th. Stryker’s dividend payout ratio (DPR) is presently 28.45%.

TRADEMARK VIOLATION NOTICE: This report was first posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this report on another site, it was stolen and republished in violation of US & international trademark & copyright law. The original version of this report can be accessed at https://theolympiareport.com/2019/02/11/ramsay-stattman-vela-price-inc-sells-802-shares-of-stryker-co-syk.html.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

Recommended Story: What are catch-up contributions?

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK).

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.